Introduction: A Paradigm of Drug Repurposing
Recently, according to the public notice released on the official website of the CDE, CSPC’s albumin-bound paclitaxel for injection (code name HB1801) is proposed to be included in the Breakthrough Therapy Designation.Image source: CDE official websiteDocetaxel, a second-generation taxane antineoplastic agent launched by Sanofi in 1995, blocks mitosis in cancer cells by promoting microtubule polymerization and inhibiting depolymerization. It is clinically indicated for multiple tumor types, including breast cancer, non-small cell lung cancer, prostate cancer, and gastric cancer, making it one of the cornerstone chemotherapeutic agents.The domestic market for injectable docetaxel has long been a highly homogenized "red ocean." Twenty companies, including Huisu Pharmaceutical, Hengrui Medicine, Chia Tai Tianqing, Zishan Pharmaceutical, and Qilu Pharmaceutical, hold approval documents. In the national centralized procurement, the winning bid price for docetaxel injection has plummeted to single-digit levels, leaving virtually no growth narrative in this niche segment of conventional injections.Image Source: Yaozhi Data - China Marketed Drug DatabaseIn the niche segment of albumin-bound docetaxel, no products have been approved globally to date. CSPC is the fastest-moving player and the first company worldwide to obtain clinical trial approvals from both Chinese and U.S. regulatory authorities.CSPC and Alphamab Oncology have collaborated to develop the HER2 bispecific antibody anitumumab (KN026), which pairs HB1801 as a fixed combination partner. They have launched multiple Phase III registration studies in breast cancer, including first-line and neoadjuvant settings. Notably, the neoadjuvant therapy study (KN026-004) announced in April 2026 that it had met its primary endpoint: the total pathological complete response (tpCR) rate of the combination regimen demonstrated statistically and clinically significant improvement compared to the control group (trastuzumab + pertuzumab + docetaxel ± carboplatin).Image Source: Yaozhi Data - Clinical Results Analysis SystemFrom injectables to albumin-bound formulations, CSPC is seeking a differentiated path for docetaxel, a mature molecule. This “mature molecule + novel formulation” strategy hinges not on the originality of the pharmacological mechanism, but on formulation technology and clinical development capabilities—areas where leading Chinese pharmaceutical companies have been gradually strengthening their expertise in recent years.Disclaimer: This article is for informational purposes only and does not represent the views of this platform. It is also not a recommendation for treatment plans. For guidance on treatment plans,Please seek medical attention at a legitimate hospital. For any issues related to the content, copyright, or other matters, please leave a message on this platform, and we will verify and address it promptly.
Responsible Editor | Xiao ErCollaboration, Submissions, Reposting Permissions | Teacher Chen 17308362010 (WeChat ID same as phone number)
![]()
